An economic evaluation for prevention of diabetes mellitus in a developing country: A modelling study

BMC Public Health

Volumn 13, Issue 1, 2013, Pages

  Liu, Xiaoqian ^a   Li, Changping ^a   Gong, Hui ^a   Cui, Zhuang ^a   Fan, Linlin ^a   Yu, Wenhua ^a   Zhang, Cui ^b   Ma, Jun ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b NANKAI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT;

ADULT; CHINA; COST BENEFIT ANALYSIS; COST OF ILLNESS; DEVELOPING COUNTRY; DIABETES MELLITUS, TYPE 2; DIET; ECONOMICS; EXERCISE; FEMALE; GLUCOSE INTOLERANCE; HUMAN; LIFESTYLE; MALE; PROBABILITY; PROCEDURES; QUALITY ADJUSTED LIFE YEAR; STATISTICS AND NUMERICAL DATA;

ADULT; CHINA; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; DIABETES MELLITUS, TYPE 2; DIET; EXERCISE; FEMALE; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; MALE; MARKOV CHAINS; QUALITY-ADJUSTED LIFE YEARS;

EID: 84881082392     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-13-729     Document Type: Article

References (60)

1. Diabetes prevention should be a public-health priority. Weber BM, Narayan K, Lancet 2008 371 473 474 18262037 (Pubitemid 351199883)
2. Epidemic obesity and type 2 diabetes in Asia. Yoon K, Lee J, Kim J, Cho JH, Choi Y, Ko S, Zimmet P, Son H, Lancet 2006 368 1681 1688 10.1016/S0140-6736(06)69703-1 17098087 (Pubitemid 46048556)
3. Prevalence of diabetes among Men and women in China. Yang WY, Lu JM, Weng JP, Jia WP, Ji LN, Xiao JZ, Shan ZY, Liu J, Tian HM, Ji QH, Zhu DL, Ge JP, Lin LX, Chen L, Guo XH, Zhao ZG, Li Q, Zhou ZG, Shan GG, He J, New Engl J Med 2010 362 1090 1101 10.1056/NEJMoa0908292 20335585
4. Achieve great success, and blaze a trail: review of clinical and basic research progress of Chinese diabetes in the 21st century. Wen-ying Y, Chin Med J 2009 122 2525 2529 19951564
5. Type 2 diabetes mellitus in China: a preventable economic burden. Wang W, McGreevey WP, Chaowei F, Zhan S, Luan R, Chen W, Biao X, AJMC 2009 15 593 601
6. Direct health care costs of diabetic patients in Spain. Oliva J, Molina B, Lobo F, Monereo S, Diabetes Care 2004 27 2616 2621 10.2337/diacare.27.11.2616 15504995 (Pubitemid 39441460)
7. Economic costs of diabetes in the U.S. In 2007. Association AD, Diabetes Care 2007 31 596 615
8. The cost burden of diabetes mellitus: the evidence from Germany-the CoDiM Study. Köster I, von Ferber L, Ihle P, Schubert I, Hauner H, Diabetologia 2006 49 1498 1504 10.1007/s00125-006-0277-5 16752168 (Pubitemid 43848085)
9. Medical care and payment for diabetes in China: enormous threat and great opportunity. Yang W, Zhao W, Xiao J, Li R, Zhang P, Kissimova-Skarbek K, Schneider E, Jia W, Ji L, Guo X, Shan Z, Liu J, Tian H, Chen L, Zhou Z, Ji Q, Ge J, Chen G, Brown J, PLoS One 2012 7 2 13
10. Cost-effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Ramachandran A, Snehalatha C, Yamuna A, Mary S, Ping Z, Diabetes Care 2007 30 2548 2552 10.2337/dc07-0150 17670917 (Pubitemid 47547791)
11. The 10-year cost-effectiveness of lifestyle intervention or Metformin for diabetes prevention. Group TDPPR, Diabetes Care 2012 35 723 730 22442395
12. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao H, Liu PG, Jiang XG, Jiang YY, Zheng H, Bennett PH, Howard BV, Diabetes Care 1997 20 537 544 10.2337/diacare.20.4.537 9096977 (Pubitemid 27143412)
13. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, Khunti K, BMJ 2007 334 299 10.1136/bmj.39063.689375.55 17237299 (Pubitemid 46293963)
14. Prevention of type 2 diabetes mellitus by changers in lifestyle among subjects with impaired glucose tolerance. Jaakko T, Jaanal L, Eriksson JG, Timot V, Helena H, Pirjo IP, Sirkka KK, Mauri L, Anne L, Merja R, IS, Matti U, New Engl J Med 2001 344 1343 1350 10.1056/NEJM200105033441801 11333990 (Pubitemid 32378388)
15. Prevention of Type 2(non-insulin-dependent) diabetes mellitus by diet and physical exercise. Eriksson K-F, Lindgiirde E, Diabetologia 1991 34 891 898 10.1007/BF00400196 1778354
16. Ruduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Group DPPR, New Engl J Med 2002 346 393 403 11832527
17. Screening for diabetes. Association AD, Diabetes Care 2002 25 Suppl 1 21 24
18. Richard K, Peter A, David E, Knut BJ, John B, JF, Edward G, Rury RH, Sue K, Michael S, Jaakko T, Nick JW, Lancet 2010 375 1365 1374 10.1016/S0140- 6736(09)62162-0 20356621
19. A computer simulation model for cost-effectiveness analysis of mass screening for Type 2 diabetes mellitus. Tony HHC, Yen MF, Tung TH, Diabetes Res Clin Pract 2001 54 Suppl 1 1 3 11532324
20. The cost-effectiveness of screening for DM 2 diabetes. Group CDC-ES, JAMA 1998 260 1757 1764
21. An economic analysis of interventions for diabetes. Klonoff DC, Schwartz DM, Diabetes Care 2000 23 390 404 10.2337/diacare.23.3.390 10868871 (Pubitemid 30131750)
22. A Markov chain model to assess the efficacy of screening for non-insulin dependent diabetes mellitus (NIDDM). Kuo HS, Chang HJ, Chou P, Tenga L, Chen TH, Int J Epidemiol 1999 28 233 240 10.1093/ije/28.2.233 10342684 (Pubitemid 29176649)
23. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Hoerger TJ, Russell H, Katherine AH, Katrina D, Stephen S, Michael E, Ann Intern Med 2004 140 689 -710 10.7326/0003-4819-140-9-200405040-00008 15126252
24. Screening for type 2 diabetes: literature review and economic modelling. Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, John A, Health Technl Asses 2007 11 1 144
25. What determines the cost-effectiveness of diabetes screening? Glumer C, Yuyun M, Griffin S, Farewell D, Spiegelhalter D, Kinmonth AL, Wareham NJ, Diabetologia 2006 49 1536 1544 10.1007/s00125-006-0248-x 16752172 (Pubitemid 43848089)
26. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. Gillies CL, Lambert PC, Abrams KR, Sutton AJ, Cooper NJ, Hsu RT, Davies MJ, Khunti K, BMJ 2008 336 1180 1185 10.1136/bmj.39545.585289.25 18426840 (Pubitemid 351809280)
27. Archimedes Model [ http://www.archimedesmodel.com/ ]
28. Markov models in medical decision making: A practical guide. Sonnenberg FA, Robert J, Med Decis Making 1993 13 322 338 10.1177/0272989X9301300409 8246705 (Pubitemid 24013155)
29. An introduction to markov modelling for economic evaluation. Andrew Briggs MS, Pharmacogenomics 1998 13 397 409
30. Impaired glucose tolerance and its relationship to ECG-indicated coronary heart disease and risk factors among Chinese. Pan X, Yi H, Li G, Liu P, Bennett PH, Howard BV, Diabetes Care 1993 16 150 156 10.2337/diacare.16.1.150 8422770 (Pubitemid 23013840)
31. Onset of NIDDM occurs at least 4-7 years before clinical diagnosis. Harris MI, Klein R, Welborn TA, Knuiman MAW, Diabetes Care 1992 15 815 819 10.2337/diacare.15.7.815 1516497
32. Epidemiological characteristics of diabetes mellitus and impaired glucose regulation in a Chinese adult population: the Shanghai Diabetes Studies, a cross-sectional 3-year follow-up study in Shanghai urban communities. Jia WP, Pang C, Chen L, Bao YQ, Lu JX, Lu HJ, Tang JL, Wu YM, Zuo YH, Jiang SY, Xiang KS, Diabetologia 2007 50 286 292 10.1007/s00125-006-0503-1 17180353
33. The rising prevalence of diabetes and impaired glucose tolerance. Dunstan DW, Zimmet PZ, Welborn TA, Courten MD, Cameron AJ, Sicree RA, Dwyer T, Colagiuri S, Jolley D, Knuman M, Atkins R, Shaw JE, iabetes care 2002 25 829 834 10.2337/diacare.25.5.829 (Pubitemid 41094278)
34. The natural history of impaired glucose tolerance in the pima Indians. Mohammed FS, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH, New Engl J Med 1988 319 1500 1506 10.1056/NEJM198812083192302 3054559 (Pubitemid 19003408)
35. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing diabetes prevention study: a 20-year follow-up study. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, Li H, Li H, Jiang Y, An Y, Shuai Y, Zhang B, Zhang JJ, Thompson TJ, Gerzoff RB, Roglic G, Hu YH, Bennett P, Lancet 2008 371 1783 1789 10.1016/S0140-6736(08)60766-7 18502303 (Pubitemid 351697954)
36. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing diabetes prevention outcome study. Gong Q, Gregg EW, Wang J, An Y, Zhang P, Yang W, Li H, Jiang Y, Shuai Y, Zhang B, Zhang J, Gerzoff RB, Gogic G, Hu Y, Li G, Bennett PH, Diabetologia 2011 54 300 307 10.1007/s00125-010-1948-9 21046360
37. The publicity medicine prices of hunan [ http://www.hnyyjg.com/ ]
38. Yi K, The diabetes community prevention and cure item cost measures to calculate to analyze with result in FengXian area Public Health Department: phD thesis, FuDan University 2008
39. A national catalog of preference-based scores for chronic conditions in the United States. Sullivan PW, Lawrence WF, Ghushchyan V, Med Care 2005 43 736 749 10.1097/01.mlr.0000172050.67085.4f 15970790 (Pubitemid 40993769)
40. Preference-based EQ-5D index scores for chronic conditions in the United States. Sullivan PW, Ghushchyan V, Med Decis Making 2006 26 410 420 10.1177/0272989X06290495 16855129 (Pubitemid 44050845)
41. Cai Y, National and provincial life tables derived from China 2000 census date Beijing: China Statistics Press 2005
42. Costing and perspective in published cost-effectiveness analysis. Neumann PJ, Med Care 2009 47 Suppl 1 28 S32 19536023
43. Quality-adjust life years. Yolanda BV, Sculpher M, Pract Neurol 2008 8 175 182 10.1136/pn.2007.140186 18502950 (Pubitemid 351850376)
44. A comparison of health-related quality of life of elderly and younger adults with diabetges. Trief PM, Wade MJ, Pine D, Weinstock RS, Age Ageing 2003 32 613 618 10.1093/ageing/afg105 14600002 (Pubitemid 37461569)
45. Normal fasting plasma glucose levels and Type 2 diabetes in yong men. Tirosh A, Shai I, Tekes-Manova D, Israeli E, Pereg D, Shochat T, Kochba I, Rudich A, New Engl J Med 2005 353 145 162 10.1056/NEJMoa042283 16014884 (Pubitemid 41058346)
46. Venkat Narayan KM, Zhang P, Kanaya AM, Williams DE, Engelgau MM, Imperatore G, Ramachandran A, Disease control porioties in developing countries Washington DC: a compubication of Oxford University Press and The World Bank 2006
47. Prevalence of type 2 DM in mainland China, Hong Kong, and Taiwan. Wong KC, Wang Z, Diabetes Res Clin Pr 2006 73 126 134 10.1016/j.diabres.2006.01.007 (Pubitemid 43928160)
48. Diabetes should public-health prority. Weber MB, Narayan KMV, Lancet 2008 371 473 474 18262037
49. Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive services task force. Russell Harris KD, Rathore SS, Frame P, Woolf SH, Lohr KN, Ann Int Med 2003 138 215 229 10.7326/0003-4819-138-3- 200302040-00015 12558362 (Pubitemid 36231628)
50. China health system performance. Liu Y, Rao K, Wu J, Gakidou E, Lancet 2008 6736 61367 61368
51. Standards of medical care in diabetes-2012. Association AD, Diabetes Care 2012 35 Suppl 1 11 S63 22187469
52. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis. Palmer AJ, Tucker DM, Prim Care Diabetes 2012 6 109 121 10.1016/j.pcd.2011.10.006 22153888
53. Potential savings in Mexico from screening and prevention for early diabetes and hypertension. Castro-Rios A, Vladislavovna Doubova S, Martinez-Valverde S, Coria-Soto I, Perez-Cuevas R, Health Aff 2010 12 2171 2179
54. Intensive lifestyle changes or metformin in patients withimpaired glucose tolerance. Palmer AJ, Roze S, Valentine WJ, Spinas GA, Shaw JE, Zimmet PZ, Clincal Therapeutics 2004 26 305 321
55. Pharmacologic management of the older patient with type 2 diabetes mellitus. Neumiller JJ, Setter SM, Am J Geriatr Pharmacotber 2009 7 324 342 10.1016/j.amjopharm.2009.12.002
56. Influence of patient characteristics on assessment of diabetes self-management support. Wallace A, Perkhounkova Y, Tseng H, Schillinger D, Nurs Res 2013 62 106 114 10.1097/NNR.0b013e3182843b77 23458908
57. Comparing three measures of health status (perceived health with likert-type scale, EQ-5D, and number of chronic conditions) in Chinese and white Canadians. Leung B, Luo N, So L, Quan H, Med Care 2007 45 610 617 10.1097/MLR.0b013e3180331f58 17571009
58. Racial and ethnic differences in preference-based health status measure. Fu AZ, Fu MWK, Curr Med Res Opln 2006 22 2439 3447 10.1185/030079906X148391 (Pubitemid 46048359)
59. Health care expenditures from living longer-how much do they matter. Gandjour A, Int J Health Plann Manage 2013 [Epub ahead of print] 10.1002/hpm.2164
60. Unrelated medical costs in Life-Years gained. Rappange DR, Job N, van Exel A, Feenstra TL, Rutten1 FFH, Brouwer WBF, Pharmacoeconomics 2008 26 815 830 10.2165/00019053-200826100-00003 18793030